Earticle

현재 위치 Home

Review Article

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy

첫 페이지 보기
  • 발행기관
    한국운동재활학회 바로가기
  • 간행물
    JER KCI 등재 바로가기
  • 통권
    Vol.12 No.3 (2016.06)바로가기
  • 페이지
    pp.143-147
  • 저자
    Su Jin Kim, Ju Ho Kim, Hyun-Kyung Chang, Khae Hawn Kim
  • 언어
    영어(ENG)
  • URL
    https://www.earticle.net/Article/A278709

※ 기관로그인 시 무료 이용이 가능합니다.
※ 학술발표대회집, 워크숍 자료집 중 4페이지 이내 논문은 '요약'만 제공되는 경우가 있으니, 구매 전에 간행물명, 페이지 수 확인 부탁 드립니다.

4,000원

원문정보

초록

영어
As the radical prostatectomy (RP) for the patient diagnosed as localized prostate cancer has been increasing, erectile dysfunction (ED) associat-ed with RP is increased and ED after RP is a significant risk factor to re-duce the quality of life for the patient after RP. Therefore, the treatment concept called penile rehabilitation was introduced and phosphodies-terase type 5 inhibitor (PDE5I) is used widely for the prostate cancer pa-tient after RP. Generally PDE5I is considered as safe and effective drug for the prostate cancer patient after RP. Recently, a report against the general opinion that PDE5I use is safe in the patient with prostate cancer was reported and the analysis of 5-yr biochemical recurrence-free sur-vival after RP between the PDE5I users and non-PDE5I users after bilat-eral nerve sparing RP showed decreased 5-yr biochemical recur-rence-free survival in the PDE5I users. In addition, a longitudinal cohort study reported that sildenafil, a kind of PDE5I, use might be associated with the development of melanoma and this result suggested the possi-bility of adverse effect of PDE5I on some kinds of cancers as well as prostate cancer. Moreover, the studies to evaluate the influence of nitric oxide (NO) and guanosine monophosphate (cGMP) signaling pathway associated with PDE5 showed both cancer reduction and cancer devel-opment. Therefore, the role of NO and cGMP signaling pathway in can-cer was reviewed based on the previous studies and suggested the ne-cessity of further clinical studies concerning about the safety of PDE5I in prostate cancer.

목차

ABSTRACT
 INTRODUCTION
 NITRIC OXIDE AND GUANOSINE MONOPHOSPHATE SIGNALING PATHWAY; ANTICANCER OR CANCER?
 PHOSPHODIESTERASE TYPE 5 INHIBITOR AND MELANOMA
 CONCLUSION
 CONFLICT OF INTEREST
 ACKNOWLEDGMENTS
 REFERENCES

키워드

Phosphodiesterase type 5 inhibitor Prostate cancer Bio-chemical recurrence

저자

  • Su Jin Kim [ Department of Urology and Catholic Fertiltiy Care Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, ]
  • Ju Ho Kim [ Department of Urology, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea ]
  • Hyun-Kyung Chang [ Department of Urology, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea ]
  • Khae Hawn Kim [ Department of Urology, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea ] Corresponding author

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국운동재활학회 [Korean Society of Exercise Rehabilitation]
  • 설립연도
    2004
  • 분야
    의약학>재활의학
  • 소개
    한국운동재활학회는 사회적, 정신적, 신체적 통합건강복지 이론의 학술연구와 회원 상호간 학술교류 증진을 장려함으로써 학문적 발전을 도모하고 나아가 건강복지선진국 발전에 이바지함을 목적으로 한다.

간행물

  • 간행물명
    JER [Journal of Exercise Rehabilitation]
  • 간기
    격월간
  • pISSN
    2288-176X
  • eISSN
    2288-1778
  • 수록기간
    2013~2026
  • 등재여부
    SCOPUS,KCI 등재
  • 십진분류
    KDC 517 DDC 613

이 권호 내 다른 논문 / JER Vol.12 No.3

    피인용수 : 0건 (자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      출처 : 네이버학술정보

        0개의 논문이 장바구니에 담겼습니다.

        페이지 저장
        소속기관 조회
        이용자님의 소속기관(단체)이 서비스에 가입되어 있는지 확인해 보십시오.
        기관회원에 소속되어 있는 이용자는 원문을 무료로 이용할 수 있습니다.